Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II AZD0530 plus carboplatin + paclitaxel in platinum-sensitive advanced ovarian cancer
2007-005325-30Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ovarian cancer comparing AZD0530 + carboplatin + paclitaxel with Placebo + carboplatin + paclitaxel (2 arms). Primary endpoint: Objective tumour response rate (RECIST). Started Oct 2007; status: completed.
02
Drugs
saracatinib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2007-005325-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005325-30.